Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $57.37 USD
Change Today +0.61 / 1.07%
Volume 242.3K
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDY) Snapshot

Open
$57.13
Previous Close
$56.76
Day High
$57.60
Day Low
$57.13
52 Week High
04/13/15 - $60.85
52 Week Low
05/27/14 - $38.92
Market Cap
9.8B
Average Volume 10 Days
285.3K
EPS TTM
--
Shares Outstanding
170.3M
EX-Date
08/1/14
P/E TM
--
Dividend
$0.29
Dividend Yield
0.51%
Current Stock Chart for DOCTOR REDDY'S LAB-ADR (RDY)

Related News

No related news articles were found.

doctor reddy's lab-adr (RDY) Related Businessweek News

No Related Businessweek News Found

doctor reddy's lab-adr (RDY) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

Founded in 1984

doctor reddy's lab-adr (RDY) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Member ...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

doctor reddy's lab-adr (RDY) Key Developments

Dr. Reddy's Laboratories Ltd. - Analyst/Investor Day

Dr. Reddy's Laboratories Ltd. - Analyst/Investor Day

Dr. Reddy's Laboratories Limited Recommends Final Dividend for the Financial Year 2014-15

Dr. Reddy's Laboratories Limited has informed that the Board of Directors of the company at its meeting held on May 12, 2015 have recommended a final dividend of INR 20 (400%) per equity share of INR 5 face value, for the financial year 2014-15.

Dr. Reddy's Laboratories Ltd. Reports Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2015

Dr. Reddy's Laboratories Ltd. reported audited standalone and consolidated earnings results for the fourth quarter and year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales /income from operations of INR 26,612 million compared to INR 25,322.7 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 6,193.3 million compared to INR 5,322.7 million a year ago. Profit from ordinary activities before tax was INR 6,878.2 million against INR 5,971.4 million a year ago. Net profit was INR 5,714.2 million or INR 33.40 per diluted share before and after extraordinary items compared to INR 4,714.3 million or INR 27.59 per diluted share before and after extraordinary items a year ago. For the year, on standalone basis, the company reported net sales /income from operations of INR 98,873.9 million compared to INR 94,957.2 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 19,007.7 million compared to INR 23,812.4 million a year ago. Profit from ordinary activities before tax was INR 20,598.2 million against INR 24,543.9 million a year ago. Net profit was INR 16,793.5 million or INR 98.18 per diluted share before and after extraordinary items compared to INR 19,328.4 million or INR 113.13 per diluted share before and after extraordinary items a year ago. For the quarter, on consolidated basis, the company reported net income from sales and services of INR 38,704.4 million compared to INR 34,809 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 6,119.6 million compared to INR 5,856.5 million a year ago. Profit from ordinary activities before tax was INR 5,930.2 million against INR 6,068.3 million a year ago. Net profit attributable to the equity holders of the company was INR 5,188.4 million or INR 30.35 per diluted share before and after extraordinary items compared to INR 4,816.0 million or INR 28.22 per diluted share before and after extraordinary items a year ago. EBITDA was INR 8,064 million compared to INR 7,942 million a year ago. Capital expenditure for the quarter was at $39 million. For the year, on consolidated basis, the company reported net income from sales and services of INR 148,188.9 million compared to INR 132,170.3 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 26,286.0 million compared to INR 26,032.1 million a year ago. Profit from ordinary activities before tax was INR 28,162.6 million against INR 26,605.7 million a year ago. Net profit attributable to the equity holders of the company was INR 22,178.6 million or INR 129.75 per diluted share before and after extraordinary items compared to INR 21,514.5 million or INR 126.04 per diluted share before and after extraordinary items a year ago. EBITDA was INR 36,170 million compared to INR 33,180 million a year ago. CapEx was INR 9.3 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $57.37 USD +0.61

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,765 INR +13.45
Cipla Ltd/India 678.70 INR +4.80
Croda International PLC 2,927 GBp 0.00
Endo International PLC $84.92 USD -0.08
Symrise AG €57.87 EUR -0.264
View Industry Companies
 

Industry Analysis

RDY

Industry Average

Valuation RDY Industry Range
Price/Earnings 27.5x
Price/Sales 4.1x
Price/Book 5.5x
Price/Cash Flow 27.4x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.